CMV-specific Cell-Mediated Immunity at 3-month Prophylaxis Withdrawal Discriminates D+/R+ Kidney Transplants at risk of Late-onset CMV Infection Regardless the Type of Induction Therapy

Background Whether CMV-specific cell-mediated immunity (CMI) at prophylaxis cessation predicts D+/R+ kidney transplants (KTR) at risk of late-onset CMV infection after receiving distinct induction therapies is still not well characterized. Methods We prospectively assessed CMV-specific CMI predicting late-onset CMV infection at prophylaxis withdrawal and at earlier time-points, in 96 consecutive D+/R+ patients receiving either antiinterleukin 2-receptor antibody (anti-IL2RA; n=50) or rabbit antithymoglobulin (rATG; n=46). CMV-specific CMI was evaluated against CMV antigens (IE-1, pp65) using an IFN-γ ELISpot assay. Results 14/96(14.6%) patients developed late-onset CMV infection and 2/96(2.1%) displayed disease. At 3 months, CMV-specific CMI frequencies were significantly lower in patients developing late-onset CMV infection (p

https://ift.tt/2PvoRL8